Clearmind Medicine Secures $1.35M in Discounted Convertible Note Financing
CMND sits 55% above its 52-week low of $2.1.
Summary
Clearmind Medicine Inc. raised $1.35 million through the issuance of discounted convertible promissory notes, a highly dilutive financing event for the micro-cap company.
Key Events · Financing and Capital Events · CMND
-
Secured $1.35 Million in Cash
The company entered into an agreement to issue $1.5 million in convertible promissory notes, receiving $1.35 million in cash (a 10% discount to principal).
-
Significant Dilution Risk
The cash raised represents approximately 41.8% of the company's current market capitalization, indicating a highly dilutive financing event.
-
Follows Recent Reverse Stock Split
This dilutive financing occurs shortly after a 1-for-10 reverse stock split, effective May 21, 2026, which was undertaken to meet Nasdaq's minimum bid price requirement.
-
Continuation of Existing Program
This transaction is part of a previously announced program to issue up to $10 million in convertible promissory notes, highlighting an ongoing reliance on dilutive financing.
Analysis · CMND · Life Sciences
Clearmind Medicine Inc. has secured $1.35 million in cash by issuing $1.5 million in convertible promissory notes at a 10% discount. This represents a substantial capital raise relative to the company's small market capitalization, indicating an urgent need for funding. The discounted terms and the dilutive nature of convertible notes, especially following a recent 1-for-10 reverse stock split, suggest ongoing financial pressure and could lead to significant dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMND was trading at $3.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.2M. The 52-week trading range was $2.10 to $524.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.